PT15 - CUMULATIVE ATHEROGENIC INDEX OF PLASMA AND RISK OF SARCOPENIA IN MIDDLE-AGED AND ELDERLY INDIVIDUALS: INSIGHTS FROM CHARLS

PT15

CUMULATIVE ATHEROGENIC INDEX OF PLASMA AND RISK OF SARCOPENIA IN MIDDLE-AGED AND ELDERLY INDIVIDUALS: INSIGHTS FROM CHARLS

F. Xu^1,*, J. Zhang¹, Q. Qiu¹, C. Hua¹, W. LI¹, J. Liu¹, G. Chen¹, O. Princess², Q. Zhao², H. Xie¹

¹The Affiliated Tongren Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, ²Anhui Medical University, Hefei, China

Rationale: The study aimed to investigate the relationship between cumulative atherogenic index of plasma (CumAIP) exposure and the incidence of sarcopenia in middle-aged and elderly individuals during follow-up.

Methods: The study cohort was derived from the China Health and Retirement Longitudinal Study (CHARLS) database. Participant stratification into five trajectory clusters was achieved through application of k-means clustering algorithm based on longitudinal variations in AIP profiles, Multivariable-adjusted logistic regression models coupled with restricted cubic spline (RCS) analytical were implemented to quantify the dose-response relationship between CumAIP exposure and sarcopenia progression. Population stratification analyses were further undertaken to examine potential heterogeneity in AIP-sarcopenia associations across demographic subgroups.

Results: Spanning a median duration of 3.7 years, 227 of 4456 participants developed sarcopenia. After adjusting for multiple confounding variables, the odds ratio (OR) for Class 1, indicative of good control, was 1.76 (95% CI, 1.21–2.57) compared to Class 2 using Class 2 as a reference group,; for Class 3, representing moderate control, the OR was 1.76 (95% CI, 1.19–2.64); for Class 4, indicative of poor control, the OR was 3.57 (95% CI, 1.85–7.43); and for Class 5, characterized by consistently high levels, the OR was 4.76 (95% CI, 2.76–8.72). The restricted cubic spline regression analysis revealed a linear relationship between CumAIP exposure and the development of sarcopenia. Furthermore, subgroup analyses yielded consistent findings across various demographic factors. 

Conclusion:  CumAIP is strongly associated with the development of sarcopenia. High CumAIP exposure increases the risk of sarcopenia, progressive elevation in CumAIP is strongly associated with amplified risks of sarcopenia.

Disclosure of Interest: None declared